"Pyridines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
| Descriptor ID |
D011725
|
| MeSH Number(s) |
D03.383.725
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyridines".
Below are MeSH descriptors whose meaning is more specific than "Pyridines".
This graph shows the total number of publications written about "Pyridines" by people in this website by year, and whether "Pyridines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 1999 | 3 | 2 | 5 |
| 2000 | 1 | 1 | 2 |
| 2001 | 4 | 0 | 4 |
| 2002 | 0 | 2 | 2 |
| 2003 | 1 | 1 | 2 |
| 2004 | 1 | 3 | 4 |
| 2005 | 2 | 5 | 7 |
| 2006 | 0 | 2 | 2 |
| 2007 | 1 | 4 | 5 |
| 2008 | 6 | 5 | 11 |
| 2009 | 2 | 4 | 6 |
| 2010 | 4 | 0 | 4 |
| 2011 | 3 | 2 | 5 |
| 2012 | 4 | 2 | 6 |
| 2013 | 4 | 3 | 7 |
| 2014 | 5 | 3 | 8 |
| 2015 | 5 | 9 | 14 |
| 2016 | 4 | 6 | 10 |
| 2017 | 4 | 4 | 8 |
| 2018 | 5 | 7 | 12 |
| 2019 | 4 | 7 | 11 |
| 2020 | 3 | 4 | 7 |
| 2021 | 5 | 6 | 11 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 6 | 6 |
| 2024 | 5 | 5 | 10 |
| 2025 | 3 | 5 | 8 |
| 2026 | 3 | 3 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyridines" by people in Profiles.
-
CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials. Lancet Oncol. 2026 May; 27(5):592-603.
-
The SCD1 inhibitor aramchol interacts with regorafenib and metformin to kill tumor cells. Oncotarget. 2026 Mar 27; 17(1):78-89.
-
Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2+ breast cancer: TBCRC049 phase 2 study results. Nat Cancer. 2026 Mar; 7(3):424-434.
-
TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer. ESMO Open. 2026 Apr; 11(4):106063.
-
The Impact of Elexacaftor-Tezacaftor-Ivacaftor on Biochemical Surrogates of Cystic Fibrosis Hepatobiliary Involvement: A Retrospective Cohort Study. Pediatr Pulmonol. 2026 Feb; 61(2):e71522.
-
Evaluating the Antiproliferative Effects of Tri(2-Furyl)- and Triphenylphosphine-Gold(I) Pyridyl- and Pyrimidine-Thiolate Complexes. Biomolecules. 2026 01 15; 16(1).
-
Selpercatinib Increases Radioactive Iodine Avidity in RET-Fusion Pediatric Thyroid Carcinoma. Pediatrics. 2025 Dec 01; 156(6).
-
Impact of elexacaftor/tezacaftor/ivacaftor on biomarkers of cystic fibrosis hepatobiliary involvement in the PUSH study. J Pediatr Gastroenterol Nutr. 2026 Feb; 82(2):350-357.
-
NF1-depleted ER+ breast cancers are differentially sensitive to CDK4/6 inhibitors. Sci Transl Med. 2025 Aug 27; 17(813):eadq5492.
-
Combinatorial therapy regimens targeting preclinical models of melanoma resistant to immune checkpoint blockade. J Clin Invest. 2025 Sep 16; 135(18).